Non-Homologous DNA End Joining in Anticancer Therapy

E-ISSN： 1873-5576|7|3|243-250

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.7, Iss.3, 2007-05, pp. : 243-250

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Triphlorethol-A Improves the Non-Homologous End Joining and Base-Excision Repair Capacity Impaired by Formaldehyde

By Zhang Rui Kang Kyoung Ah Piao Mei Jing Kim Ki Cheon Lee Nam Ho You Ho Jin Hyun Jin Won

Journal of Toxicology and Environmental Health, Vol. 74, Iss. 12, 2011-01 ,pp. : 811-821

Taylor & Francis Ltd

Access to resources Recommend Favorite

Evaluation of Thermal Cisplatin Sensitization in Chicken DT40 Cells, Normal and Deficient, in DNA Homologous and Nonhomologous Endjoining Repair

Letters in Drug Design & Discovery, Vol. 2, Iss. 3, 2005-05 ,pp. : 196-200

Bentham Science Publishers

Access to resources Recommend Favorite

DNA Repair Helicases as Targets for Anti-Cancer Therapy

Current Medicinal Chemistry, Vol. 14, Iss. 5, 2007-02 ,pp. : 503-517

Bentham Science Publishers

Access to resources Recommend Favorite

Acute non-myelosuppressive complications of systemic anticancer therapy

By Rea Daniel

Clinical Medicine, Vol. 8, Iss. 4, 2008-08 ,pp. : 439-442

Royal College Of Physicians

Access to resources Recommend Favorite

DNA-drug Conjugates for Site-specific Delivery in Anti-cancer Therapy

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 14, Iss. 2, 2017-04 ,pp. : 68-73

Bentham Science Publishers

Access to resources Recommend Favorite